Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Aptus Pharma IPO
Price Band
₹65.0–70.0
Issue Size
₹13.02 Cr
Lot Size
2,000 shares
Min Investment
₹280,000
2 LOTS MIN
GMP
+₹4.0 (5.71%)
Issue Price
₹70.0
Subject to Sauda
₹6100
Paid only if allotted
Aptus Pharma IPO AI Summary
- Aptus Pharma IPO is listed on BSE SME in the Pharmaceuticals sector.
- Price band: ₹65.0–₹70.0 per share, lot size 2,000 shares (min. investment ₹280,000, 2 lots minimum).
- Subscription window: 23 Sep–25 Sep 2025, listing on 30 Sep 2025.
- Current GMP is +₹4.0 (5.71%), an estimated listing price of ₹74 — unofficial and can change daily.
Aptus Pharma Ltd is a pharmaceutical company with a diverse range of products and a strong distribution network. The IPO is priced at ₹70.0, with a minimum investment of ₹280,000 and a lot size of 2000 shares. The company has shown consistent growth in revenue and profitability over the past few years.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Aptus Pharma IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 25 Sep 2025 — not a current signal.
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Aptus Pharma IPO Grey Market Premium (GMP) Today
GMP
+₹4.0
GMP %
+5.71%
Est. Listing
₹74.0
Updated: 25 Jul 2026 14:12
About the Company
Incorporated in 2010, Aptus Pharma Ltd is engaged in the business of marketing, and distribution of finished pharmaceutical formulations The company manufactures and distributors of a broad range of pharmaceutical formulations covering multiple therapeutic areas: antacids & PPIs, pain management, anti-inflammatories, antibiotics, cardiology & antidiabetics, neuropsychiatry, dental, injectable parenterals, syrups, nutraceuticals, sachets, and more. Products: Aptus Pharma: Focuses on acute therapies i.e, anti-infectives, pain management, etc. Aptus CD care: Focused on chronic therapies Aptus Wellcare: Offers wellness and nutraceutical products Aptus Global: Export in overseas market As of March 31, 2025, the company has 194 pharmaceutical formulations in more than eleven therapeutic segments. Its warehouse is located over 15,732 sq. Feet and 1989 sq. feet in Ahmedabad, Gujarat. Its distribution model includes 125 direct and sub distributors and a sales team of 54 field personnel. As of March 31, 2025, the company had 70 employees. Competitive Strengths Diversified product portfolio Robust distribution network Strategic manufacturing alliances across Gujarat, Uttarakhand and Himachal Pradesh Competitive and cost-effective pricing Experienced management team
Company Financials (₹ Cr)
As of 2025-03-31
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 21.92 | 10.03 | 6.22 |
| Total Income | 24.64 | 17.88 | 13.90 |
| Profit After Tax | 3.10 | 0.80 | 0.19 |
| EBITDA | 4.76 | 1.49 | 0.57 |
| NET Worth | 6.97 | 1.77 | 0.97 |
| Reserves and Surplus | 1.97 | 1.47 | 0.67 |
| Total Borrowing | 10.36 | 5.31 | 2.21 |
Key Ratios
EPS
₹6.20
NAV
₹13.93
ROE
44.50%
ROCE
45.66%
RoNW
44.50%
P/E Ratio
11.29
Market Cap
₹48.02 Cr
PAT Margin
12.62%
Debt/Equity
1.49
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Lincoln Pharmaceuticals Limited | 335.34 | 12.26% | 13.53 | 41.11 | 41.11 |
| Sunrest Lifescience Limited | 37.72 | 12.36% | 10.56 | 4.66 | 4.66 |
| Zota Health Care Limited | 110.83 | 2.72% | 382.12 | 3.16 | 3.16 |
| Aptus Pharma Limited This IPO | 13.93 | 44.5% | — | 5.32 | 5.32 |
Promoters
Kunjal Piyushbhai Unadkat, Tejash Maheshchandra Hathi, Chatrabhuj Vallabhbhai Butani, Kapilbhai Hasmukhbhai Chandarana, Ghanshyam Vinubhai Pansuriya, Milly Chetan Lalseta, Riddhish Natwarlal Tanna, Gaurang Rameshchandra Thakker and Kripaliben Mayank Thakker
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Capital Expenditure for Office Premises with furniture and Industrial Racks 1.63 2 Working Capital 8.00 3 General Corporate Purposes 1.91 4 Issue Expenses 1.48 Total 13.02
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹13.90 Cr in the year ended 31 Mar 2023, increasing to ₹17.88 Cr by 31 Mar 2024, and further rising to ₹24.64 Cr by 31 Mar 2025. This shows a consistent growth in revenue over the periods.
Profit Trend
Profit After Tax was ₹0.19 Cr for the year ending 31 Mar 2023, which increased to ₹0.80 Cr by 31 Mar 2024, and further to ₹3.10 Cr by 31 Mar 2025. This indicates a significant upward trend in profitability.
Valuation
Aptus Pharma has an implied P/E of approximately 11.29 at the issue price, compared to peers trading within a P/E range of 10.56 to 382.12.
Grey Market Premium, Explained
The Grey Market Premium (GMP) indicates the price at which shares are expected to trade in the unofficial market before listing. A positive GMP suggests that there is demand for the shares, while a negative GMP may indicate weak interest.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their overall portfolio strategy and risk tolerance.
Who May Want to Wait
Those who prefer stable investments with lower risk may want to avoid IPOs, as they can be subject to significant price fluctuations shortly after listing.
Listing Gains — The Risk
Listing gains refer to the potential profit an investor can make when shares are listed on the stock exchange. However, these gains are not guaranteed and can be influenced by market conditions, investor sentiment, and the company's performance post-listing.
This evaluation is generated from Aptus Pharma's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Aptus Pharma IPO GMP today?
Aptus Pharma IPO GMP today is +₹4.0 (5.71%), indicating an estimated listing price of ₹74. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Aptus Pharma IPO?
The price band of Aptus Pharma IPO is ₹65.0–₹70.0 per share.
When does Aptus Pharma IPO open and close?
Aptus Pharma IPO opens on 23 September 2025 and closes on 25 September 2025.
When does Aptus Pharma IPO list on the stock exchange?
Aptus Pharma IPO listed on 30 September 2025 at ₹74.0.
What is the lot size for Aptus Pharma IPO?
The lot size for Aptus Pharma IPO is 2000 shares, requiring a minimum investment of ₹280,000 (2 lots).
What is the price band for the IPO?
The price band for the IPO is ₹65.0 to ₹70.0.
What is the minimum investment required?
The minimum investment required is ₹280,000.
What is the lot size for the IPO?
The lot size for the IPO is 2000 shares.
What is the expected listing date?
The expected listing date is September 30, 2025.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected price movement of the shares before they officially list.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
23 Sep 2025
Close
25 Sep 2025
Allotment
26 Sep 2025
Listing
30 Sep 2025
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Aptus Pharma?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.